相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Differences in Sustained Cellular Effects of MET inhibitors Are Driven by Prolonged Target Engagement and Lysosomal Retention
Nina Berges et al.
MOLECULAR PHARMACOLOGY (2023)
Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy
Chaofan Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2023)
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
Joachim Albers et al.
MOLECULAR CANCER THERAPEUTICS (2023)
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
Julien Mazieres et al.
JAMA ONCOLOGY (2023)
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
Julien Mazieres et al.
JAMA ONCOLOGY (2023)
Kincore: a web resource for structural classification of protein kinases and their inhibitors
Vivek Modi et al.
NUCLEIC ACIDS RESEARCH (2022)
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
Luckson N. Mathieu et al.
CLINICAL CANCER RESEARCH (2022)
Achievements and challenges of the Sakigake designation system in Japan
Mototsugu Tanaka et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Discovery of 5-{2-[5-Chloro-2-(5-ethoxyquinoline-8-sulfonamido)phenyl]ethynyl}-4-methoxypyridine-2-carboxylic Acid, a Highly Selective in Vivo Useable Chemical Probe to Dissect MCT4 Biology
Timo Heinrich et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Structural basis of the activation of c-MET receptor
Emiko Uchikawa et al.
NATURE COMMUNICATIONS (2021)
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
Wenyuan Xiong et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting MET Dysregulation in Cancer
Gonzalo Recondo et al.
CANCER DISCOVERY (2020)
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
Toshio Fujino et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors
Gavin W. Collie et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
KinaMetrix: a web resource to investigate kinase conformations and inhibitor space
Rayees Rahman et al.
NUCLEIC ACIDS RESEARCH (2019)
Identification of Methionine Aminopeptidase-2 (MetAP-2) Inhibitor M8891: A Clinical Compound for the Treatment of Cancer
Timo Heinrich et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Alexis B. Cortot et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Alexis B. Cortot et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D. Engstrom et al.
CLINICAL CANCER RESEARCH (2017)
Homogeneous time-resolved G protein-coupled receptor-ligand binding assay based on fluorescence cross-correlation spectroscopy
Thomas Antoine et al.
ANALYTICAL BIOCHEMISTRY (2016)
Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844)
Antonio Ugolini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
cMET Exon 14 Skipping: From the Structure to the Clinic
Nele Van der Steen et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors
Dieter Dorsch et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Physiological Signaling and Structure of the HGF Receptor MET
Gianluca Baldanzi et al.
BIOMEDICINES (2015)
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
J. Jean Cui
JOURNAL OF MEDICINAL CHEMISTRY (2014)
EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Friedhelm Bladt et al.
CLINICAL CANCER RESEARCH (2013)
Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
Lipika Goyal et al.
CLINICAL CANCER RESEARCH (2013)
Data processing and analysis with the autoPROC toolbox
Clemens Vonrhein et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients
Ralph Tiedt et al.
CANCER RESEARCH (2011)
Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met
Keith W. Rickert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
XDS
Wolfgang Kabsch
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors
Sergei L. Timofeevski et al.
BIOCHEMISTRY (2009)
Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases
Fawn Qian et al.
CANCER RESEARCH (2009)
Inference of macromolecular assemblies from crystalline state
Evgeny Krissinel et al.
JOURNAL OF MOLECULAR BIOLOGY (2007)
Phaser crystallographic software
Airlie J. McCoy et al.
JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)
Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase
WR Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
In-gel digestion for mass spectrometric characterization of proteins and proteomes
Andrej Shevchenko et al.
NATURE PROTOCOLS (2006)
Regulation of the wild-type and Y1235D mutant met kinase activation
C Cristiani et al.
BIOCHEMISTRY (2005)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Mutations in the met oncogene unveil a dual switch mechanism controlling tyrosine kinase activity
F Chiara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
